Alex J. Carlisle, Ph.D
Chief Scientific Officer for Precision Health, Northrop Grumman
EP3 Foundation Board Member
Dr. Alex Carlisle holds a Doctorate in Biochemistry and Molecular Biology from Howard University and has spent the past 17 years developing and applying translational and clinical research approaches in the areas of molecular oncology and neuroscience. Dr. Carlisle received his post-doctoral training at the NIH where he served at the NCI as a leading member of the Cancer Genome Anatomy Project, and at the National Institute for Neurological Disorders and Stroke.
Dr. Carlisle went on to Fox Chase Cancer Center and later joined the Children’s Hospital of Philadelphia. Dr. Carlisle then moved to Inova Fairfax Hospital, serving as the Department of Neuroscience’s first Principle Investigator for the Inova-George Mason University Neuroscience Translational Research Laboratory. At Inova, he served as director of the Laboratory of Neuro-Oncology where he directed research programs in Neuroblastoma and Traumatic Brain Injury and continues to serve as an Affiliate Professor of Molecular Neuroscience in George Mason University’s Krasnow Institute.
Dr. Carlisle joined Northrop Grumman Corporation in 2013 as a Senior Scientific Advisor for their Health IT unit and currently serves as Chief Scientific Officer and Program Manager for Precision Healthcare, leading their efforts to deliver scientific and analytic solutions focused on integrating big data across the patient healthcare ecosystem.
Dr. Carlisle is an active Board Member of the Leukemia & Lymphoma Society (LLS), the EP3 Foundation, and National Alliance against Disparities in Patient Health (NADPH).